logo BDSP

Base documentaire


  1. Incidence of second cancers in patients treated for Hodgkin's disease.

    Article - En anglais

    Purpose 

    We studied the association between treatment for Hodgkin's disease and the incidence of second cancers.

    Methods 

    We conducted a study within a cohort that included 10 472 patients from 14 cancer centers in the United States and Canada who were first diagnosed as having Hodgkin's disease at some point from 1940 through 1987.

    Discounting the 1st year after diagnosis, the average length of follow-up was 7.1 years per subject.

    Results 

    We observed 122 leukemias and 438 solid tumors.

    Conclusions 

    Procarbazine, chlorambucil, and vinblastine are associated with increased leukemia risk.

    Combination drug regimens have leukemogenic effects estimated as the product of RRs for individual drugs.

    Chemotherapy and radiotherapy increase the risk of selected solid tumors, and the effect of chemotherapy on solid tumor risk is weaker than the leukemogenic effect.

    Implications : Without doubt, the benefits of treatment of Hodgkin's disease outweigh the risk of a subsequent malignancy, but data on the carcinogenic effects of radiation and drugs beyond 10 years after treatment continue to be sparse, and future analyses should be directed at long-term survivors. [J Natl Cancer Inst 87 : 732-741,1995].

    Mots-clés Pascal : Hodgkin maladie, Second cancer, Leucémie, Tumeur maligne, Incidence, Epidémiologie, Procarbazine, Agent alkylant, Vinblastine, Alcaloïde, Chlorambucil, Anticancéreux, Carcinogenèse, Chimiothérapie, Radiothérapie, Etats Unis, Amérique du Nord, Amérique, Canada, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome

    Mots-clés Pascal anglais : Hodgkin disease, Second cancer, Leukemia, Malignant tumor, Incidence, Epidemiology, Alkylating agent, Alkaloid, Antineoplastic agent, Carcinogenesis, Chemotherapy, Radiotherapy, United States, North America, America, Canada, Human, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0452446

    Code Inist : 002B19B. Création : 01/03/1996.